Latest filings (excl ownership)
424B4
Prospectus supplement with pricing info
23 Apr 24
EFFECT
Notice of effectiveness
23 Apr 24
POS AM
Prospectus update (post-effective amendment)
19 Apr 24
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
19 Apr 24
POS AM
Prospectus update (post-effective amendment)
11 Apr 24
EFFECT
Notice of effectiveness
3 Apr 24
S-1/A
IPO registration (amended)
27 Mar 24
ARS
2023 FY
Annual report to shareholders
21 Mar 24
DEFA14A
Additional proxy soliciting materials
21 Mar 24
DEF 14A
Definitive proxy
21 Mar 24
10-K
2023 FY
Annual report
21 Mar 24
8-K
Biolase Reports Full-year 2023 Results; Expects Continued Revenue Growth In 2024
21 Mar 24
PRE 14A
Preliminary proxy
8 Mar 24
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
5 Mar 24
8-K
Other Events
27 Feb 24
8-K
Other Events
21 Feb 24
8-K
BIOLASE, Inc. Announces Pricing of $7.0 Million Public Offering
15 Feb 24
424B1
Prospectus with pricing info
14 Feb 24
EFFECT
Notice of effectiveness
14 Feb 24
S-1/A
IPO registration (amended)
9 Feb 24
CORRESP
Correspondence with SEC
9 Feb 24
S-1/A
IPO registration (amended)
7 Feb 24
8-K
Results of Operations and Financial Condition
7 Feb 24
S-1/A
IPO registration (amended)
30 Jan 24
8-K
Biolase Reports Unaudited Revenue Growth for Full Year 2023 and Provides
29 Jan 24
S-8
Registration of securities for employees
24 Jan 24
UPLOAD
Letter from SEC
24 Jan 24
S-1
IPO registration
19 Jan 24
8-K
Departure of Directors or Certain Officers
29 Dec 23
S-1
IPO registration
26 Dec 23
D
$2.73 mm in equity / options / securities to be acquired, sold $2.73 mm, 1 investor
20 Dec 23
8-K
Biolase, Inc. Announces Pricing of $1.4 Million Registered Direct
8 Dec 23
424B5
Prospectus supplement for primary offering
8 Dec 23
8-K
Entry into a Material Definitive Agreement
17 Nov 23
10-Q
2023 Q3
Quarterly report
9 Nov 23
8-K
Results of Operations and Financial Condition
9 Nov 23
8-K
BIOLASE Inc. Announces Pricing of $4.5 Million
18 Sep 23
424B1
Prospectus with pricing info
15 Sep 23
424B1
Prospectus with pricing info
15 Sep 23
POS EX
Additional exhibits for listing
14 Sep 23
Latest ownership filings
SC 13G
S.H.N. Financial Investments Ltd.
23 Feb 24
SC 13G
Lind Global Fund II LP
21 Feb 24
SC 13G
Anson Funds Management LP
14 Feb 24
SC 13G/A
LYTTON LAURENCE W
14 Feb 24
SC 13G/A
Lind Global Fund II LP
13 Feb 24
SC 13G/A
Krefta Edson Roberto
10 Oct 23
3
Initial statement of insider ownership
6 Oct 23
SC 13G
Krefta Edson Roberto
12 Sep 23
4
Kenneth P. Yale
12 Jun 23
4
Martha J. DDS, PhD Somerman
12 Jun 23
4
JESS ROPER
12 Jun 23
4
Kathleen T OLoughlin
12 Jun 23
4
Carol Gomez DDS Summerhays
12 Jun 23
4
JONATHAN T MD LORD
12 Jun 23
4
Steven Sandor
6 Jun 23
4/A
Jennifer Bright
6 Jun 23
4
Jennifer Bright
6 Jun 23
4
JOHN R BEAVER
6 Jun 23
4
Change in insider ownership
26 May 23
SC 13G/A
PERKINS CAPITAL MANAGEMENT INC
15 May 23
SC 13G
PERKINS CAPITAL MANAGEMENT INC
9 Feb 23
SC 13G
LYTTON LAURENCE W
20 Jan 23
SC 13G
Lind Global Fund II LP
13 Jan 23
4
JONATHAN T MD LORD
8 Dec 22
4
Jennifer Bright
12 Aug 22
4
Steven Sandor
12 Aug 22
4
JOHN R BEAVER
12 Aug 22
3
Steven Sandor
14 Jul 22
3
Jennifer Bright
14 Jul 22
4
Carol Gomez DDS Summerhays
13 May 22
4
Kenneth P. Yale
13 May 22
4
Martha J. DDS, PhD Somerman
13 May 22
4
Kathleen T OLoughlin
13 May 22
4
JESS ROPER
13 May 22
4
JONATHAN T MD LORD
12 May 22
3
Kenneth P. Yale
3 May 22
4
JONATHAN T MD LORD
2 May 22
4
JESS ROPER
2 May 22
4
JOHN R BEAVER
2 May 22
SC 13G/A
ARMISTICE CAPITAL, LLC
15 Feb 22